ArticleTransplantation direct2026
The Association Between Variability in Tacrolimus Trough Levels and Posttransplant Diabetes Mellitus in Thai Kidney Transplant Patients.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tacrolimus (TAC) trough-level variability has been associated with patient outcomes and renal graft survival. However, its relationship with posttransplant diabetes mellitus (PTDM) remains unclear. This study aims to evaluate the association between the coefficient of variation (CV) of TAC (TAC-CV) and the incidence of PTDM within the first year after kidney transplantation (KT). Methods: A multicenter retrospective study was conducted on 516 Thai KT patients who received TAC-based immunosuppressive regimens from 2011 to 2020, with a 1-y post-KT follow-up period. TAC-CV was calculated for the 0-12 mo post-KT period, and optimal cutoff values were determined using receiver operating characteristic analysis. Results: Of the 516 patients, 208 (40.31%) developed PTDM, whereas 308 (59.69%) did not during the first year post-KT. Significant associations were found between TAC-CV and PTDM throughout the study period ( Conclusions: These findings suggest that TAC-CV may serve as a valuable marker for identifying patients at high risk of PTDM and may aid in its prevention and effective management in KT recipients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.